Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

4Total
Not Applicable (1)
P 1 (1)
P 2 (2)

Trial Status

Recruiting2
Unknown1
Active Not Recruiting1

Clinical Trials (4)

Showing 4 of 4 trials
NCT06416007Phase 2Recruiting

Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

NCT06440005Phase 1Recruiting

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

NCT05032092Not ApplicableActive Not RecruitingPrimary

Evaluation of Efficacy of Comprehensive Genomic Tumour Profiling (CGP) From Liquid and/or Tissue Biopsy in Patients With Locally Advanced and/or Metastatic Solid Cancer

NCT05469061Phase 2Unknown

Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC

Showing all 4 trials

Research Network

Activity Timeline